報價延遲最少15分鐘:2025/05/10 05:33 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
9.39 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.51/1.59
|
|
企業價值
908.47M
|
| 資產負債 |
|
每股賬面淨值
0.76
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
169.12M
|
|
每股收益
0.02
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/10 05:33 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. |